137 related articles for article (PubMed ID: 16081472)
41. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
Bladé J; San Miguel JF; Escudero ML; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti JM; Rozman C; Estapé J; Montserrat E
Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202
[TBL] [Abstract][Full Text] [Related]
42. Interferon alpha in the therapy of multiple myeloma.
Gisslinger H
Leukemia; 1997 Dec; 11 Suppl 5():S52-6. PubMed ID: 9436940
[TBL] [Abstract][Full Text] [Related]
43. Novel agents and the paradigm of continuous treatment in multiple myeloma.
Palumbo A
Leuk Res; 2012 Nov; 36 Suppl 1():S1-2. PubMed ID: 23176718
[No Abstract] [Full Text] [Related]
44. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
Hájek R; Adam Z; Vásová I; Král Z
Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281
[TBL] [Abstract][Full Text] [Related]
45. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
Zee B; Cole B; Li T; Browman G; James K; Johnston D; Sugano D; Pater J
J Clin Oncol; 1998 Aug; 16(8):2834-9. PubMed ID: 9704736
[TBL] [Abstract][Full Text] [Related]
46. Maintenance therapy in multiple myeloma.
Mihelic R; Kaufman JL; Lonial S
Leukemia; 2007 Jun; 21(6):1150-7. PubMed ID: 17344913
[TBL] [Abstract][Full Text] [Related]
47. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
48. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.
Myeloma Trialists' Collaborative Group
Br J Haematol; 2001 Jun; 113(4):1020-34. PubMed ID: 11442498
[TBL] [Abstract][Full Text] [Related]
49. [Analysis of results of drug therapy for symptomatic multiple myeloma].
Lysenko LB; Nikolaeva N; Pushkareva TF; Kapuza EA; Shatokhina ON; Kozyuk OV; Dmitrieva VV; Snezhko TA; Novoselova KA
Vopr Onkol; 2015; 61(4):667-70. PubMed ID: 26571842
[TBL] [Abstract][Full Text] [Related]
50. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
Vesole DH; Crowley JJ; Catchatourian R; Stiff PJ; Johnson DB; Cromer J; Salmon SE; Barlogie B
J Clin Oncol; 1999 Jul; 17(7):2173-9. PubMed ID: 10561273
[TBL] [Abstract][Full Text] [Related]
51. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
52. Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma.
McSweeney EN; Tobias JS; Blackman G; Goldstone AH; Richards JD
Clin Oncol (R Coll Radiol); 1993; 5(6):378-83. PubMed ID: 8305360
[TBL] [Abstract][Full Text] [Related]
53. Thalidomide in multiple myeloma.
Rajkumar SV
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
[TBL] [Abstract][Full Text] [Related]
54. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
Kagoya Y; Nannya Y; Kurokawa M
Leuk Res; 2012 Aug; 36(8):1016-21. PubMed ID: 22579366
[TBL] [Abstract][Full Text] [Related]
55. Treatment for elderly patients with multiple myeloma.
Tsubokura M; Kami M
Lancet; 2008 Mar; 371(9617):983; author reply 984-5. PubMed ID: 18358919
[No Abstract] [Full Text] [Related]
56. Whither interferon for myeloma and other hematologic malignancies?
Alexanian R; Weber D
Ann Intern Med; 1996 Jan; 124(2):264-5. PubMed ID: 8534004
[No Abstract] [Full Text] [Related]
57. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
[TBL] [Abstract][Full Text] [Related]
58. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein.
Sangfelt O; Osterborg A; Grandér D; Anderbring E; Ost A; Mellstedt H; Einhorn S
Int J Cancer; 1995 Oct; 63(2):190-2. PubMed ID: 7591202
[TBL] [Abstract][Full Text] [Related]
59. [Standard treatment of multiple myeloma].
Facon T
Rev Med Interne; 1999 Jul; 20(7):611-21. PubMed ID: 10434353
[TBL] [Abstract][Full Text] [Related]
60. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
